Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

Some Daylight for Vitamin D? New Analysis Hints at Small CVD Benefit

Michael O'Riordan

June 30, 2023

News Daily News

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Yael L. Maxwell

June 23, 2022

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Daily News

Postmenopausal Women See Added ASCVD Risk After Complicated Pregnancies

Caitlin E. Cox

September 18, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Daily News

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

L.A. McKeown

October 30, 2018

News Daily News

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

Todd Neale

September 13, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

Advertisement

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Some Daylight for Vitamin D? New Analysis Hints at Small CVD Benefit

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Postmenopausal Women See Added ASCVD Risk After Complicated Pregnancies

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Recurrent Events Common Among Young Patients With CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Study Questions Role of BP Meds in Patients With Hypertension but No Other CVD Risk Factors

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content